Floatz logo

HUMAN NATURAL KILLER CELL LINE NK-92 (CD16.158V, ER IL2) CELLS

Non-Small Cell Lung Carcinoma

ImmunityBio, Inc.Cell therapyPhase 2Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
65/ 100

Competitive context

1206 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
Veliparib
AbbVie
Phase 3BBB

View all 50 →

Same molecule, other indications

HUMAN NATURAL KILLER CELL LINE NK-92 (CD16.158V, ER IL2) CELLS is also rated in:

triple-negative breast carcinomaDormant
C
Indicative ·
37 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
33 / 100
View asset →
non-Hodgkin lymphomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →